Mirati Therapeutics Inc.
(NASDAQ : MRTX)

( )
MRTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-3.80%191.441.2%$534.16m
TSROTESARO, Inc.
0.23%73.9514.4%$516.06m
CELGCelgene Corporation
-3.74%70.081.2%$510.98m
GILDGilead Sciences, Inc.
-2.91%68.150.9%$491.90m
ILMNIllumina, Inc.
-3.86%321.413.5%$363.96m
BIIBBiogen Inc.
-3.05%316.731.3%$352.14m
REGNRegeneron Pharmaceuticals, Inc.
-2.32%372.832.6%$248.08m
VRTXVertex Pharmaceuticals Incorporated
-4.12%172.211.9%$245.33m
AAgilent Technologies, Inc.
-2.34%70.231.5%$233.08m
ALXNAlexion Pharmaceuticals, Inc.
-4.49%115.602.0%$139.06m
SRPTSarepta Therapeutics, Inc.
-3.35%121.3815.4%$129.29m
NKTRNektar Therapeutics
-2.76%36.995.5%$106.49m
EXASExact Sciences Corporation
-4.30%71.7025.3%$105.84m
INCYIncyte Corporation
-0.91%64.512.5%$103.69m
LGNDLigand Pharmaceuticals Incorporated
-5.19%145.6123.1%$85.50m

Company Profile

Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.